About Paul Fonteyne
Paul Fonteyne is a co-founder and director of Allyx Therapeutics, which develops oral medicines for Alzheimer’s and other neurodegenerative diseases. He is also an independent director at Apnimed, a clinical-stage drug company developing oral treatments for obstructive sleep apnea. Fonteyne serves as an executive in residence at Canaan Partners, an early-stage health care and technology venture fund.
Fonteyne has more than 30 years in biopharma, including 15 years in U.S. and global leadership roles at Boehringer-Ingelheim. He became president and chief executive officer of its U.S. business in November 2011. He later served as chairman and retired in January 2019. Earlier, he held commercial leadership roles for nine years at Merck and eight years at Abbott Laboratories. He also worked as Allyx’s business and strategy advisor. His other current biotechnology boards include Apellis, Amylyx and Ypsomed. He also served on PhRMA’s board and chaired the National Pharmaceutical Council.
Experience
This experience comes from official bios, from Paul Fonteyne's profile and from SEC filings. For roles taken from filings, the years are when the filings name Paul Fonteyne in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Paul Fonteyne works with at each company, as listed on that company's latest Form D.
